High-efficiency platforms for personalized cervix cancer treatment
Official title: Developing Clinical High Efficiency Platforms for Individualised Treatment Through Integration of Advanced Radiation Technology, Quantitative Imaging and Molecular Biology and Machine Learning for Treatment of Cervix Cancer.
Run by Tata Memorial Hospital · NCT05102240 · Data updated 2026-11-12
This project will use past patient imaging and treatment records to build machine-learning tools that predict tumor response and normal tissue side effects for people treated for cervix cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | Women only |
| Enrollment | 1800 (estimated) |
| Sponsor | Tata Memorial Hospital Government |
| Drugs / interventions | radiation |
| Locations | 1 site (Navi Mumbai, Maharashtra) |
| Status | Recruiting |
| Started | February 24, 2022 |
| Main results expected | June 30, 2026 |
| Study ends | June 30, 2026 |
| Registry record updated | February 20, 2026 |
| Trial ID | NCT05102240 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Patients with cervix cancer who were treated within completed or ongoing chemoradiation or brachytherapy protocols and who have MRI/CT imaging and documented outcome data in the hospital database are appropriate for inclusion.
✕Probably not a fit
Patients without available imaging or outcome records in the hospital database or those treated outside the radiotherapy/brachytherapy protocols used in the datasets are unlikely to be included or to benefit from the models.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This retrospective observational project uses imaging (MRI and CT), treatment plans, and outcome data from completed and ongoing cervix cancer radiotherapy and brachytherapy protocols. Machine learning will be applied to automate tumor and organ-at-risk delineation, to develop normal tissue complication probability (NTCP) and tumor control probability (TCP) models, and to extract quantitative texture features for response prediction. The team will also create a library of proton beam plans to compare achievable doses and identify patients likely to benefit from proton therapy. Models will be trained and validated on the available institutional datasets and linked clinical endpoints.
Why it matters
Potential benefit: If successful, the tools could enable more precise targeting, better prediction of toxicities and responses, and help select patients who may benefit from intensified or proton therapy.
How similar studies have gone: Machine-learning methods for auto-contouring and toxicity prediction have shown promise in other radiotherapy settings, but comprehensive integration for cervix cancer and proton-plan selection is still relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: For Aim 1 and Aim 3: * Patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer with access to MRI/CT images at the time of diagnosis and brachytherapy For Aim 2 * Patients undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT. Exclusion Criteria: 1. Lack of disease or toxicity outcomes. 2. Lack of images in the hospital database.
Where it's running
-
Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre
Navi Mumbai, Maharashtra, India Recruiting
Study contacts
- Principal investigator: Supriya Sastri (nee Chopra), MD — Tata Memorial Centre, The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
- Study coordinator: Supriya Sastri (nee Chopra), MD
- Email: supriyasastri@gmail.com
- Phone: 02227405000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Shorter pelvic radiotherapy after surgery for cervical or endometrial cancer
A randomized study tests whether a shorter course of postoperative whole-pelvic radiotherapy can be as safe and effective as the standard longer schedule for women with cervical or endometrial cancer.
-
Late radiation side effects after postoperative IMRT and brachytherapy for cervical and endometrial cancer
This project will see how often and how severe late gastrointestinal and urinary side effects are in people with cervical or endometrial cancer who received postoperative IMRT and/or brachytherapy at Tata Memorial Hospital.
-
Comparing clinic-only versus clinic plus community outreach to offer HPV self-collection for cervical screening in women with HIV
This project will test whether adding community health worker outreach to clinic services helps more women living with HIV complete HPV self-collection for cervical screening.
-
Outcomes for Oligometastatic and Oligorecurrent Cervical Cancer
This registry will see if adding local treatments such as radiation or surgery to standard systemic therapy helps people with oligo‑metastatic or oligo‑recurrent cervical cancer live longer or avoid progression.
-
Hyaluronic acid gel spacer to protect nearby organs during cervical cancer radiation
This pilot tests a hyaluronic acid gel spacer (Barrigel) to see if it helps people with cervical cancer receiving chemoradiotherapy and brachytherapy by creating space between the tumor and nearby organs.
-
Short-course (hypofractionated) versus standard radiotherapy with cisplatin and brachytherapy for locally advanced cervical cancer in Uganda
This trial tests whether a shorter, higher-dose radiotherapy schedule plus cisplatin and brachytherapy works as well and causes no more serious side effects than the usual longer schedule for women in Uganda with stage IB3–IIIC cervical cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.